For women with metastatic breast cancer, the prognosis can be grim. And while survival rates have increased in the last few decades, the five-year relative survival among women aged 15-49 is just 36 percent.NuGenerex Immuno-Oncology (formerly Antigen Express) is hoping to increase that number by...
You are here
ANTIGEN EXPRESS, INC.
Company Information
Address
ANTIGEN EXPRESS, INC.
100 BARBER AVE
WORCESTER, MA
01606
United States
Information
UEI: N/A
# of Employees: N/A
Ownership Information
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
li Suppression-enhanced HIV DNA Vaccine
Amount: $354,100.00DESCRIPTION (provided by applicant): Antigen Express scientists have discovered that cells expressing MHC class II molecules in the absence of the MHC class II-associated Ii protein can act as effecti ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
HER-2/neu T Helper/Memory Vaccine for Breast Cancer
Amount: $224,700.00DESCRIPTION (provided by applicant): Antigen Express scientists have demonstrated that the li-Key segment of the li protein, acting at an allosteric site of Class II molecules, facilitates charging b ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
li-Key/Melanoma MHC Class II Vaccines
Amount: $444,070.00DESCRIPTION (provided by applicant): MHC-presented peptide vaccines are one of the most promising experimental therapies for melanoma. However, MHC class I peptides that prime CTLs lack dramatic anti- ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
HIV LI-KEY/PEPTIDE VACCINE
Amount: $301,761.00Antigen Express scientists have discovered that a segment of the Ii protein called Ii-Key, which acts at an allosteric site on one end of the antigenic peptide binding site on MHC Class II molecules, ...
SBIRPhase I2002Department of Health and Human Services National Institutes of Health -
PROSTATE CANCER VACCINE BY SUPPRESSING Ii PROTEIN
Amount: $191,744.00DESCRIPTION: Suppressing the Ii protein by anti-sense oligonucleotides in MHC class Il-positive cancer cells creates a potent cancer cell vaccine. Presumably, additional determi ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health -
COMBINED IL-2 AND MHC CLASS II GENE THERAPY FOR CANCER
Amount: $287,382.00DESCRIPTION: Antigen Express has developed technology to force the presentation of endogenous tumor antigens in a manner that produces an effective tumor cell vaccine. The key to this strat ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health -
N/A
Amount: $173,340.00N/A
SBIRPhase I2000Department of Health and Human Services National Institutes of Health -
IMPROVING DNA VACCINES FOR HIV1
Amount: $100,000.00N/A
SBIRPhase I1998Department of Health and Human Services -
IIKEY PEPTIDE THERAPEUTICS
Amount: $100,000.00A new class of immunotherapeutic drugs will be designed around the IiKEY peptide to enhance or inhibit, in an MHC class II allele related manner, immune responses in several disease states. Binding o ...
SBIRPhase I1997Department of Health and Human Services
